Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL PLUS versus HYDROXYZINE.
Head-to-head clinical analysis: DRIXORAL PLUS versus HYDROXYZINE.
DRIXORAL PLUS vs HYDROXYZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.
None Documented
None Documented
Clinical Note
moderateHydroxyzine + Venlafaxine
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Venlafaxine."
Clinical Note
moderateHydroxyzine + Nefazodone
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Nefazodone."
Clinical Note
moderateHydroxyzine + Mifepristone
"Hydroxyzine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateHydroxyzine + Fesoterodine
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.
Category C
Category A/B
Antihistamine/Decongestant
Antihistamine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine."